Blood

Vol. 147, Issue 3 Issue 3 2026
16
Articles

Articles in this Issue

ML-DS 2018 TRIAL

Jan 15, 2026 pp. 317-317 10.1182/blood.2025032648

Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML

Bogdan Popescu, Matthew F. Jones, Madison Piao et al. Jan 15, 2026 pp. 276-289 10.1182/blood.2025030558

Abstract Aberrant activation of RAS/MAPK signaling limits the clinical efficacy of several targeted therapies in acute myeloid leukemia (AML). In FMS-like tyrosine kinase-3 (FLT3)-...

Duffy-null reference ranges for improved clinical care

Laura M. Raffield, Alexander P. Reiner Jan 15, 2026 pp. 224-225 10.1182/blood.2025032115

A small step yet one giant leap for cGVHD biomarkers

Igor Novitzky-Basso, Dennis Dong Hwan Kim Jan 15, 2026 pp. 217-218 10.1182/blood.2025031596

High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing

Anaïs Schavgoulidze, Aurore Perrot, Xavier Leleu et al. Jan 15, 2026 pp. 266-275 10.1182/blood.2025029999

Abstract The prognostic heterogeneity of multiple myeloma is mainly driven by the genomic features of myeloma cells. The International Myeloma Society (IMS)/International Myeloma W...

Distinct biological subtypes of chronic GVHD after pediatric hematopoietic cell transplantation

Bernard Ng, Andrew C. Harris, Sayeh Abdossamadi et al. Jan 15, 2026 pp. 241-253 10.1182/blood.2025028625

Abstract Chronic graft-versus-host-disease (cGVHD) is the primary nonrelapse limitation to a successful hematopoietic cell transplantation and is largely treated as a single biolog...

CPX-351 in Down syndrome–associated myeloid leukemia: results and prognostic factors from the phase 3 ML-DS 2018 trial

Stephanie Laszig, Antonia Diederichs, Emilia Salzmann-Manrique et al. Jan 15, 2026 pp. 229-240 10.1182/blood.2025030775

Abstract Myeloid leukemia of Down syndrome (ML-DS) is associated with an excellent prognosis but high treatment-related toxicity and mortality. The Phase 3 Clinical Trial for CPX-3...

Elevated serum erythropoietin level in JAK2+ polycythemia vera with small vessel Budd-Chiari syndrome

Yaswanta K. Gummadi, Amy M. Trottier Jan 15, 2026 pp. 316-316 10.1182/blood.2025031930

Patient-reported outcomes: a Polaris for POLARIX

Oreofe O. Odejide, Gregory A. Abel Jan 15, 2026 pp. 219-220 10.1182/blood.2025031427

miR-aculous effects for hemophilic arthropathy

Laurent O. Mosnier Jan 15, 2026 pp. 226-227 10.1182/blood.2025030987

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study

Carrie Thompson, Marek Trneny, Franck Morschhauser et al. Jan 15, 2026 pp. 254-265 10.1182/blood.2025028848

Abstract Diffuse large B-cell lymphoma (DLBCL) poses a challenge in hematology given its varied symptoms, and the complex interplay between disease and treatment effects on health-...

Multinational assessment of absolute neutrophil counts and white blood cell counts among healthy Duffy-null adults

Stephen P. Hibbs, Israel Chipare, Amr J. Halawani et al. Jan 15, 2026 pp. 290-298 10.1182/blood.2025029359

Abstract Laboratory reference intervals must reflect population diversity for accurate medical decisions. The Duffy-null variant lowers absolute neutrophil counts (ANC), but existi...

Factor VIIa–released extracellular vesicles attenuate joint bleed–induced hemophilic arthropathy

Padmavathi Kavadipula, Shiva Keshava, Kaushik Das et al. Jan 15, 2026 pp. 299-311 10.1182/blood.2024027143

Abstract Repeated bleeding into joints in hemophilia leads to chronic inflammation that plays a central role in the pathogenesis of hemophilic arthropathy (HA). Our recent studies...

Resistance is not futile: RAS inhibition resensitizes AML

Cailin Collins, Ravindra Majeti Jan 15, 2026 pp. 222-224 10.1182/blood.2025031932

Time to say adieu to FISH in myeloma diagnostics

Juan-Jose Garces, Francesco Maura Jan 15, 2026 pp. 221-222 10.1182/blood.2025031255

Prior transplantation and idecabtagene vicleucel in multiple myeloma: a secondary analysis of CIBMTR data

Rahul Banerjee, Christy Khouderchah, Othman S. Akhtar et al. Jan 15, 2026 pp. 312-315 10.1182/blood.2025031426

Abstract Recent analyses have suggested a possible negative impact of prior autologous stem cell transplantation on outcomes with idecabtagene vicleucel (ide-cel) chimeric antigen...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page